[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1- FINLAY-FR-1 (Experimental): High dose of RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. A 3rd booster dose between 2 and 4 months after the second dose.This group will be subdivided in two subgroups: one will be boosted with the same vaccine (homologous schedule) or with FINLAY-FR-1A (high dose) (heterologous schedule). Presentation: Vial with single dose. Group 2- FINLAY-FR-1A (Experimental): High dose of RBD+adjuvant A; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. A 3rd booster dose between 2 and 4 months after the second dose. Presentation: Vial with single dose. Group 3- FINLAY-FR-1A (Experimental): Low dose of RBD+adjuvant A; 0.5 mL by intramuscular route. Treatment scheme: 0-28-56 days. Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;Meningococcal Vaccines", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "High dose; 0.5 mL;2 (0-28 days);IM", "treatment_id": 514, "treatment_name": "Finlay-fr-1 anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Low dose; 0.5 mL;3 (0-28-56 days);IM", "treatment_id": 513, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "High dose; 0.5 mL;2 (0-28 days);IM", "treatment_id": 513, "treatment_name": "Finlay-fr-1a anti-sars-cov-2 vaccine", "treatment_type": "Protein subunit", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1- FINLAY-FR-1 (Experimental): High dose of RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Group 2- FINLAY-FR-1A (Experimental): High dose of RBD+adjuvant A; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Group 3- FINLAY-FR-1A (Experimental): Low dose of RBD+adjuvant A; 0.5 mL by intramuscular route. Treatment scheme: 0-28-56 days. Presentation: Vial with single dose.;Immunogenicity; Vaccine;Immunotherapy; Active;Vaccination;Injections; Intramuscular;Meningococcal Vaccines", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1- FINLAY-FR-1 (Experimental): High dose of RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Group 2- FINLAY-FR-1A (Experimental): High dose of RBD+adjuvant A; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Group 3- FINLAY-FR-1A (Experimental): Low dose of RBD+adjuvant A; 0.5 mL by intramuscular route. Treatment scheme: 0-28-56 days. Presentation: Vial with single dose;Immunogenicity; Vaccine", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]